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The aim of this study was to determine the changes of plasma lipid peroxidation, 
zinc and erythrocyte Cu-Zn superoxide dismutase activity in patients with type 2 
diabetes mellitus and healthy control in Gorgan city. Fifty type 2 patients with 
diabetes mellitus and 50 people without diabetes were included in this randomized 
study. None of patients studied had any diabetic complications. The levels 
of plasma malondialdehyde and zinc from type 2 diabetes mellitus patients 
(6.24±0.85 mnol mL-l and 116.78±5.51 µg dL-1) and control groups 
(3.63±0.97 mnol mL-l and 146.86±9.06 µg dL - 1) were determined. Erythrocyte 
Cu-Zn superoxide dismutase activity from patients with diabetes 
(675.34±60.89 U g-1 Hb) and control groups (1052.70± 52.76 U g-1 Hb) were 
determined. The increased plasma lipid peroxidation and decreased plasma zinc 
and erythrocyte Cu-Zn superoxide dismutase activity that we observed in patients 
with type 2 diabetes mellitus may predispose to the development of cardiovascular 
complications. We propose that diabetic patients may have elevated requirement 
for antioxidants. Supplementation with zinc and vitamin or dietary free radical 
scavengers such as vitamins E and C or tomato, orange and etc. have a potential 
role in boosting antioxidant-related defences and maybe important in patients 
with diabetes. 
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INTRODUCTION 
Free radicals are highly reactive molecules generated 
by biochemical redox reactions that occur as a part of 
normal cell metabolism (Kohen et al., 1996). These 
unstable species may cause oxidative damage to DNA, 
carbohydrate, proteins and lipids that are normally 
counteracted by protective antioxidants. Oxidative 
defense is provided by a number of enzymes and 
vitamins, including the vitamin E, vitamin C and 
glutathione (Halliwell, 1997; Halliwell and Gutteridge, 
1989; Sies, 1993). In times of increased free radical 
production, individuals may become deficient in these 
antioxidants. Excessive free radical production or low 
antioxidant level leads to oxidation of cellular lipids, 
proteins and nucleic acids, which results in fragmentation 
and cross-linking. This may ultimately lead to cell death 
with widespread pathological consequences (Baynes, 
1991) The imbalance between protective antioxidants 
(antioxidant defense) and increased free radical 
production, leading to oxidative damage, is knovvn as 
oxidative stress. Oxidative stress is caused by a relative 
overload of oxidants, i.e., reactive oxygen species. This 
impairs cellular fllllctions and contributes to the 
pathophysiology of many diseases. Evidence has 
accumulated suggesting that complications of diabetes 
seem to be partially mediated by oxidative stress 
(Hayoz et al., 1998; Rosen et al., 1998; 
Szaleczky et al., 1999). The function of zinc in the body 
metabolism is based on its enzymatic affinity, such as a 
zinc-enzyme complex or Zinc metalloenzyme. In humans 
and animals, diabetes maybe results in disturbance of 
these vital trace elements (Kinlaw et al., 1983). In most 
mammals, insulin is stored as zinc crystals and is likely 
secreted in zinc form. Zinc has important role in 
modulating the immlllle system and its dysfllllction in 
diabetes mellitus may be related in part to the status of 
zinc (Mocchegianai et al., 1989). Lack or inadequate 
supply of such nutrients produces fllllctional impairment 
and can result in disease. The clinical significance and 
evaluation of zinc in regard to different diseases, 
including diabetes mellitus remains conflicting as well as 
controversial. Many questions still remain unanswered. 
Several reports llllderscore the role of micronutrient 
status in patients with type 1 or 2 diabetes mellitus 
(Mooradian et al., 1994; Strain, 1991; Anderson, 1995; 
Chaumer, 1998; Anderson et al., 1997; Ravina et al., 
l 999a, b ). Zinc maybe act in normalizing glycemia and a 
restored zinc status in patients with type 2 diabetes 
mellitus may collllteract the deleterious effects of 
oxidative stress, helping to prevent many complications 
associated with diabetes. 
Diabetes mellitus is a major source of morbidity in 
developed colllltries. Morbidity and mortality are 
increased in patient with type 2 diabetes mellitus 
compared with the general population, particularly with 
respect to coronary artery disease. One possible 
explanation for this is that oxidative stress may be a 
contributory factor. There are contradictory reports on 
changes in plasma lipid peroxidation, zinc and erythrocyte 
Cu-Zn superoxide dismutase activity in patients with type 
2 diabetes. Some of the studies show an increase whereas 
others show a decrease, or no significant differences. 
There are a few reports describing differences in plasma 
lipid peroxidation, zinc and erythrocyte antioxidant 
enzymes between patients with type 2 diabetes and 
controls. Zinc as a cofactor of enzyme Cu-Zn superoxide 
dismutase is an important element for activity of this 
enzyme. Because of the contradictory results in this 
field of study, the present study was designed to 
determine the changes of plasma lipid peroxidation(by 
measuring the level of1.1DA), zinc and erythrocyte Cu-Zn 
superoxide dismutase activity in patients with type 2 
diabetes mellitus (at a diabetes center in Gorgan city) in 
comparison to controls. 
MATERIALS AND METHODS 
Samples were obtained, in a randomized fashion, 
from 50 patients with type 2 diabetes as well as 50 control 
subjects. Patients were chosen from the patients referred 
to the Department of Diabetes Center at the 5th Azar 
Hospital in Gorgan University of Medical Sciences. The 
study was carried out during 2005. The patients studied 
had no evidence of vascular complications, including 
hypertension, coronary artery disease. Controls were 
defined as not having a major medical illness, no hospital 
admissions, no current medication and a subjective 
perception of good health as determined by health 
questionnare. None of the study subjects received any 
medication and trace element supplement in the 
previous 2-3 months. Characteristics of both groups 
are shovvn in the Table 1. Blood samples were obtained 
after an overnight fast in heparinized tubes. Plasma 
was separated soon after blood was taken. The plasma 
malondialdehyde (the level of lipid peroxidation expressed 
as malondialdehyde [MDA]), fasting blood sugar (FBS) 
and erythrocyte Cu-Zn superoxide dismutase (SOD), 
glycatedhaemoglobin (HbA,,) and hemoglobin (Hb) were 
determined using laboratory kits and spectrophotometry 
techniques (model JENW A Y 6105 UV/VIS). Plasma Zinc 
(Zn) was measured using randox laboratory kit (Hamster 
and Zak, 1985) and spectrophotometry techniques. 
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Table 1: Baseline characteristic 
Characteristic Patients with diabetes Controls 
No. of subjects 50 50 
Age (}rears) 48.47±6.87 47.66±5.68 
Sex 
male 20 22 
female 30 28 
Duration of diabetes (}rears) 2.78±0.74 
FBS (mg dL-1) 204.54±32.42 85.62±8.31 
HbA1, (%2 10.67±1.06 6.31±0.83 
Plasma MDA, FBS and erythrocyte Cu-Zn SOD, HbA" 
and Hb were determined using previously described 
methods (Satoh, 1978; Banunham, l 972a, b; Wooliams et 
al., 1983; Boer et al., 1992). Data was analyzed by 
Student's !-test, using SPSS-10 software. p<0.05 was 
considered significant. 
Malondialdehyde measurement: To 0.5 rnL plasma, 2.5 rnL 
of trichloroacetic acid was added and the tube was left to 
stand for 10 min at room temperature. After centrifugation 
at 3500 RPM for 10 min, the supernatant was decanted 
and the precipitate was washed once with sulfuric acid. 
The after, 2.5 rnL sulfuric acid and 3 mL thiobarbituric acid 
(TBA) in sodium sulfate were added to the precipitate and 
the coupling of lipid peroxide with TBA was carried out in 
a boiling water bath for 30 min. After cooling in cold 
water, the resulting chromogen was extracted with 4 rnL 
of n-butyl alcohol by vigorous shaking. Separation of 
the organic phase was facilitated by centrifugation at 
3000 RPM for 10 min and its absorbance was determined 
at the wavelength of 530 rnn. 
Cu-Zn Superoxide dismutase measurement: This 
method employs xanthine and xanthine oxidase (XOD) to 
generate superoxide radicals which react with 2-( 4­
iodopheny1)-3-( 4-nitropheno1)-5-pheny1tetrazolium 
chloride (I.NT) to form a red fonuazan dye. The 
superoxide dismutase (SOD) activity is then measured 
(at 505 mu) by the degree of inhibition of this reaction. 
One rmit of SOD is that which causes a 50% inhibition of 
the rate of reduction of INT under the conditions of 
the assay. 
RESULTS AND DISCUSSION 
In the present study we determined the plasma 
levels of malondialdehyde, Zinc and erythrocyte Cu-Zn 
superoxide dismutase in 50 patients with type 2 diabetes 
mellitus (20 men and 30 women) and 50 control subjects 
(22 men and 28 women). As shown in Table 2 plasma level 
of Zn and erythrocyte SOD were significantly decreased 
and the plasma level of1.1DA was significantly increased 
in patients with diabetes compared with controls (p<O.001) 
Table 2: Plasma malondialdehyde, zinc levels and erythrocyte superoxide 
dismutase activi 
Patients with Controls 
Plasma levels diabetes (n = 38) (n = 19) p-value 
Malondialdehyde 6.24±0.85 3.63±0.97 <0.05 
(nmol mL-1) 
Zinc 116. 78±5.51 146.86±9.06 <0.05 
(µg dL-') 
Superoxide 675.34±60.89 1052.70±52.76 <0.05 
dismutase (U gr-1 Hb) 
The aim of the present study was to determine the 
plasma level of malondialdehyde, zinc and erythrocyte 
Cu-Zn supetoxide dismutase enzyme activity in patients 
with type 2 diabetes. There are a few reports describing 
difference in plasma lipid peroxidation, zinc and. 
erythrocyte Cu-Zn supetoxide dismutase enzyme activity 
between patients with type 2 diabetes versus controls. 
Some of the studies showed an increase while some other 
showed a decrease or no significant differences. 
Patients with type 2 diabetes mellitus have increased 
mortality and morbidity compared with controls and are 
more likely to suffer from coronary artery, cerebrovascular 
and peripheral vascular diseases (Kannel and McGee, 
1979). It has been proposed that oxidative stress may 
be associated with the pathogenesis of macrovascular 
complications of type 2 diabetes (Baynes, 1991; 
Giugliano et al., 1995). In people with diabetes, the 
vulnerability to oxidative damage maybe partly attributed 
to deficient antioxidant micronutrient status, including 
trace elements. Impairment of zinc (Chaumer, 1998; 
Walter et al., 1991; Bolstein-Fujii et al., 1997; Ruiz et al., 
1998) status has been reported as an aggravating factor 
1n the progression of diabetes. Although zinc may 
influence the processes associated with oxidant stress, 
the practical consequences of its status have not been 
studied extensively (DiSilvestro, 2000). 
The results of this study show that in patients with 
type 2 diabetes plasma lipid peroxidation (expressed as 
malondialdehyde) was significantly increased and that 
zinc levels were decreased compared with controls 
(p<0.05). This study also shows that the erythrocyte 
superoxide dismutase enzyme activity was decreased in 
patients with type 2 diabetes compared with controls 
(p<0.05). 
Some of the previous studies are in agreement with 
our findings of increased lipid peroxidation and decreased 
Cu-Zn superoxide dismutase activity in patients with type 
2 diabetes (Vanizor et al., 2001; Cho et al., 2002). 
Sundaram et al. (1996) studied patients with type 2 
diabetes mellitus and showed an increase in lipid 
peroxidation from the onset of disease. Study of 
Nourooz-Zadeh et al. (1997) showed that changes in lipid 
peroxidation were related to the underlying metabolic 
abnormalities in type 2 diabetes rather than to the onset 
of complications. The some studies describe that plasma 
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Zn in type 2 diabetes mellitus patients is decreased 
(Walter et al., 1991; Evliaoglu et al., 2002), whereas others 
show no significant differences (Evliaoglu et al., 2002; 
Zargar et al., 1998) compared to controls. The results of 
this study are in agreement with the results of studies 
showing that plasma Zn levels in patients with type 2 
diabetes mellitus is significantly decreased (Walter et al., 
1991; Evliaoglu et al., 2002). But our results are not in 
agreement with the other studies (Evliaoglu et al., 2002; 
Zargar et al., 1998). A possible explanation for this is that 
there is loss of a large amount of Zn from the body via 
urine. The source of the Zn that being excreted remains 
wrresolved. There is a concurrent hypozincemia and a 
decrease in tissue Zn stores. However, it is not clear if this 
results from hyperzincuria, or from an independent event, 
an insulin or hyperglycemia related induced loss of Zn 
from tissue stores. Zn would then be released into the 
plasma and thereafter excreted. This results in a net loss 
of total body Zn and eventual hypozincemia. 
Possible sources of elevated free radicals in type 2 
diabetes include increased production of radical oxygen 
species, especially from glycation or lipoxidation 
processes, auto-oxidation of glucose and oxidizing of 
glucose and decreased antioxidant defense systems 
(Giugliano et al., 1995). Improvement of glycemic control 
and supplementation with zinc appears to be a beneficial 
factor in decreasing lipid peroxidation in patients with 
diabetes. Prevention of lipid peroxidation may help to 
delay the development of diabetic complications. 
The results of this study also show that in type 2 
diabetes mellitus patients, erythrocyte Cu-Zn superoxide 
dismutase activity is decreased. Other studies have 
reported that erythrocyte superoxide dismutase activity in 
this type of patients was either decreased (Cigremis et al., 
2003; Palanduz et al., 2001 ), increased (Turk et al., 2002) 
or no significant differences were observed 
(Memisogullari et al., 2003). Possible explanations for our 
results include reduced antioxidant protection in type 2 
diabetes mellitus and/or greatly increased amollllts of free 
radicals that overwhelm the defense system. 
Other explanations include decreased activity of 
Cu-Zn superoxide dismutase related to either increased 
free radical production causing oxidation followed by 
denaturing of the enzyme, or alternatively glycation of the 
enzyme with resulting inhibition of enzymatic activity 
(Hunt and Wolff, 1991 ). Furthermore, zinc is a required 
cofactor for a variety of antioxidant enzymes, particularly 
superoxide dismutase. Alterations of zinc metabolism 
resulting in reduced availability of zinc might be expected 
contribute to tissue damage observed in diabetes 
(Surnovski et al., 1992). 
Increased lipid peroxidation, decreased plasma 
zinc and reduced erythrocyte Cu-Zn superoxide dismutase 
activity may predispose patients with type 2 diabetes 
to cardiovascular complications. These states of 
affairs may play an important role in progress of 
Cardiovascular abnormality in patients with type 2 
diabetes. We propose that patients with type 2 diadetes 
may have supraphysiological antioxidants requirements. 
Supplementation with zinc and other free radical 
scavengers such as vitamins E and C or foodstuff 
containing these, such as tomatos, oranges and similars 
have the potential to boost antioxidant defences and 
ultimately these important factors up-grade the pateints 
quality of life and prevent sudden silent myocardial 
infarction (Dieber-Rotheneder et al., 1991; Porkkala­
Sarataho et al., 1996). 
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